These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 10846432

  • 1. [Leptin and obesity: is the use of this hormone the solution to this illness?].
    González-Barranco J.
    Rev Invest Clin; 2000; 52(2):113-4. PubMed ID: 10846432
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacotherapy of obesity.
    Linné Y, Rössner S.
    Clin Dermatol; 2004; 22(4):319-24. PubMed ID: 15475233
    [Abstract] [Full Text] [Related]

  • 3. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans.
    Fogteloo AJ, Pijl H, Frölich M, McCamish M, Meinders AE.
    Diabetes Nutr Metab; 2003 Apr; 16(2):109-14. PubMed ID: 12846450
    [Abstract] [Full Text] [Related]

  • 4. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial.
    Zelissen PM, Stenlof K, Lean ME, Fogteloo J, Keulen ET, Wilding J, Finer N, Rössner S, Lawrence E, Fletcher C, McCamish M, Author Group.
    Diabetes Obes Metab; 2005 Nov; 7(6):755-61. PubMed ID: 16219020
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Obesity.
    Arterburn D.
    Clin Evid; 2002 Jun; (7):538-47. PubMed ID: 12230679
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-Acting PASylated Leptin Ameliorates Obesity by Promoting Satiety and Preventing Hypometabolism in Leptin-Deficient Lep(ob/ob) Mice.
    Bolze F, Morath V, Bast A, Rink N, Schlapschy M, Mocek S, Skerra A, Klingenspor M.
    Endocrinology; 2016 Jan; 157(1):233-44. PubMed ID: 26492472
    [Abstract] [Full Text] [Related]

  • 11. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N, Ryan DH, Renz CL, Hewkin AC.
    Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
    [Abstract] [Full Text] [Related]

  • 12. [Weight reduction. Doubly effective with drug support].
    MMW Fortschr Med; 2001 Apr 12; 143(15):42-3. PubMed ID: 11349320
    [No Abstract] [Full Text] [Related]

  • 13. Does long-term use of sibutramine (Meridia) result in continued weight loss in short-term responders?
    Stevenson JH, Trojian T, Jackson EA.
    J Fam Pract; 2001 Dec 12; 50(12):1084. PubMed ID: 11742615
    [No Abstract] [Full Text] [Related]

  • 14. [Obesity: physiology and possibilities for treatment].
    Prager R.
    Acta Med Austriaca; 1995 Dec 12; 22(5):94-5. PubMed ID: 8651044
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
    Hainer V, Kunesova M, Bellisle F, Hill M, Braunerova R, Wagenknecht M.
    Int J Obes (Lond); 2005 Feb 12; 29(2):208-16. PubMed ID: 15583700
    [Abstract] [Full Text] [Related]

  • 20. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan 12; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.